FDA Approves Novel Antibiotic Combination for Multidrug-Resistant Complicated UTIs

The U.S. Food and Drug Administration (FDA) has approved a new injectable antibiotic combination, cefepime and zidebactam, for the treatment of complicated urinary tract infections (UTIs), including pyelonephritis, caused by susceptible microorganisms. This approval marks a significant advancement in addressing the growing challenge of multidrug-resistant bacterial infections, which pose a critical threat to public health.

Addressing a Critical Healthcare Challenge

Complicated UTIs, which often require hospitalization, are increasingly driven by multidrug-resistant bacteria. According to the Centers for Disease Control and Prevention (CDC), these infections contribute to significant morbidity, mortality, and healthcare costs. The new antibiotic combination, developed by Wockhardt, offers a targeted solution for pathogens such as *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*, which are notorious for their resistance to conventional treatments.

“Multidrug-resistant bacterial infections are a substantial burden for patients and the healthcare system,” said Dr. Keith Kaye, a professor of medicine at Rutgers Robert Wood Johnson Medical School. “There is an ongoing need for new antibiotics to combat these drug-resistant pathogens, and this approval provides patients with an exciting new option.”

How the Combination Works

The cefepime-zidebactam regimen leverages a synergistic mechanism to overcome resistance. Cefepime, a fourth-generation cephalosporin, targets penicillin-binding proteins (PBPs) in gram-negative bacteria, while zidebactam, a non-beta-lactam antibacterial and beta-lactamase inhibitor, enhances its efficacy by blocking resistance mechanisms. This dual action is particularly effective against bacteria producing metallo-beta-lactamases and other resistance factors.

“This synergy occurs even in the presence of beta-lactamases and other non-enzymatic resistance mechanisms, such as hyper-efflux and downregulation of outer membrane porin channels,” the company reported.

Results from the ENHANCE-1 Trial

The FDA’s decision was informed by data from the phase 3 ENHANCE-1 trial, which evaluated the efficacy of cefepime-zidebactam against meropenem, a broad-spectrum carbapenem antibiotic. The study enrolled 529 patients with complicated UT